Janux Therapeutics’ (JANX) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research report released on Monday morning, Benzinga reports. The brokerage currently has a $100.00 target price on the stock.

A number of other analysts have also recently issued reports on the stock. Scotiabank reduced their price objective on shares of Janux Therapeutics from $47.00 to $42.00 and set a sector perform rating for the company in a research note on Friday, August 9th. HC Wainwright reiterated a buy rating and issued a $63.00 price target on shares of Janux Therapeutics in a report on Monday, August 19th. Wedbush reiterated an outperform rating and issued a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Finally, Stifel Nicolaus initiated coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They issued a buy rating and a $70.00 price target on the stock. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, Janux Therapeutics presently has a consensus rating of Moderate Buy and an average price target of $66.13.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $48.32 on Monday. The firm has a fifty day moving average price of $43.28 and a 200-day moving average price of $44.19. The stock has a market cap of $2.51 billion, a PE ratio of -39.61 and a beta of 3.57. Janux Therapeutics has a 1 year low of $5.65 and a 1 year high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.20. The firm had revenue of $8.90 million during the quarter, compared to analysts’ expectations of $0.77 million. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. Janux Therapeutics’s revenue for the quarter was up 709.1% on a year-over-year basis. On average, research analysts expect that Janux Therapeutics will post -1.18 EPS for the current year.

Insider Transactions at Janux Therapeutics

In other news, major shareholder Ventures Xi L.P. Avalon sold 158,031 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $47.00, for a total value of $7,427,457.00. Following the sale, the insider now directly owns 2,959,175 shares in the company, valued at approximately $139,081,225. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 268,578 shares of company stock worth $12,071,151 in the last three months. Insiders own 35.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

A number of large investors have recently made changes to their positions in JANX. Point72 Asset Management L.P. bought a new position in Janux Therapeutics during the 2nd quarter valued at about $5,715,000. Blue Owl Capital Holdings LP bought a new position in Janux Therapeutics during the 2nd quarter valued at about $1,676,000. The Manufacturers Life Insurance Company grew its holdings in Janux Therapeutics by 234.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,048 shares of the company’s stock valued at $1,007,000 after purchasing an additional 16,864 shares during the last quarter. AQR Capital Management LLC bought a new position in Janux Therapeutics during the 2nd quarter valued at about $215,000. Finally, Samlyn Capital LLC grew its holdings in Janux Therapeutics by 9.6% during the 2nd quarter. Samlyn Capital LLC now owns 324,703 shares of the company’s stock valued at $13,602,000 after purchasing an additional 28,312 shares during the last quarter. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.